Bill Sponsor
House Bill 5723
115th Congress(2017-2018)
Expanding Oversight of Opioid Prescribing and Payment Act of 2018
Active
Active
Passed House on Jun 19, 2018
Overview
Text
Introduced
May 9, 2018
Latest Action
Jun 20, 2018
Origin Chamber
House
Type
Bill
Bill
The primary form of legislative measure used to propose law. Depending on the chamber of origin, bills begin with a designation of either H.R. or S. Joint resolution is another form of legislative measure used to propose law.
Bill Number
5723
Congress
115
Policy Area
Health
Health
Primary focus of measure is science or practice of the diagnosis, treatment, and prevention of disease; health services administration and funding, including such programs as Medicare and Medicaid; health personnel and medical education; drug use and safety; health care coverage and insurance; health facilities. Measures concerning controlled substances and drug trafficking may fall under Crime and Law Enforcement policy area.
Sponsorship by Party
Republican
New York
Republican
South Carolina
Democrat
Washington
Republican
West Virginia
House Votes (1)
Senate Votes (0)
checkPassed on June 19, 2018
Status
Passed
Type
Voice Vote
Voice Vote
A vote in which the presiding officer states the question, then asks those in favor and against to say "Yea" or "Nay," respectively, and announces the result according to his or her judgment. The names or numbers of senators voting on each side are not recorded.
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5264)
Summary

Expanding Oversight of Opioid Prescribing and Payment Act of 2018

This bill requires the Medicare Payment Advisory Commission to report to Congress on: (1) how Medicare pays for opioid and non-opioid pain management treatments in inpatient and outpatient hospital settings; (2) current incentives for prescribing opioid and non-opioid treatments under Medicare inpatient and outpatient prospective payment systems, along with recommendations to address any identified adverse incentives; and (3) how opioid use is currently tracked and monitored through Medicare and any areas for improvement.

Text (4)
June 20, 2018
June 19, 2018
June 19, 2018
Actions (15)
06/20/2018
Received in the Senate and Read twice and referred to the Committee on Finance.
06/19/2018
Motion to reconsider laid on the table Agreed to without objection.
06/19/2018
On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote. (text: CR H5264)
06/19/2018
Passed/agreed to in House: On motion to suspend the rules and pass the bill, as amended Agreed to by voice vote.(text: CR H5264)
06/19/2018
DEBATE - The House proceeded with forty minutes of debate on H.R. 5723.
06/19/2018
Considered under suspension of the rules. (consideration: CR H5264-5265)
06/19/2018
Mr. Roskam moved to suspend the rules and pass the bill, as amended.
06/19/2018
Placed on the Union Calendar, Calendar No. 592.
06/19/2018
Committee on Energy and Commerce discharged.
06/19/2018
Reported (Amended) by the Committee on Ways and Means. H. Rept. 115-760, Part I.
05/22/2018
Referred to the Subcommittee on Health.
05/16/2018
Ordered to be Reported (Amended) by Voice Vote.
05/16/2018
Committee Consideration and Mark-up Session Held.
05/09/2018
Referred to the Committee on Ways and Means, and in addition to the Committee on Energy and Commerce, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
05/09/2018
Introduced in House
Public Record
Record Updated
Jan 11, 2023 1:39:34 PM